O013 Preliminary Results from a Phase 1 Study of ALKS 2680, an Orexin-2 receptor Agonist, in Healthy Participants and Patients with Narcolepsy or Idiopathic Hypersomnia

INTRODUCTION: ALKS 2680, a potent, brain-penetrant, highly selective orexin-2 receptor (OX2R) agonist, is being developed for treatment of narcolepsy and other hypersomnias. We report preliminary results from the ALKS 2680 first-in-human study. METHODS: This randomized, double-blind, phase 1 study o...

Descripción completa

Detalles Bibliográficos
Autores principales: Yee, B, Chapman, J, Grunstein, R, Argent, C, D’Rozario, A, Hopkinson, C, Ramos, J, Landry, I, Yagoda, S, Rege, B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Oral Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591782/
http://dx.doi.org/10.1093/sleepadvances/zpad035.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591782/
http://dx.doi.org/10.1093/sleepadvances/zpad035.013

Ejemplares similares